P. Poortmans

701 citations

26 papers · 328 indexed · h-index 9

Co-authors: Alain Fourquet W. Van den Bogaert H. Struikmans J.J. Jager Laurence Collette M. Piérart Harry Bartelink Jean-Claude Horiot
Topics: Breast Cancer Treatment Studies (12 papers)Advanced Radiotherapy Techniques (6 papers)Prostate Cancer Treatment and Research (5 papers)
Cited by: Cancer Research Pathology and Forensic Medicine Oncology
Journals: International Journal of Radiation Oncology*Biology*Physics European Journal of Cancer Radiotherapy and Oncology
Partner nations: Netherlands France Belgium

In The Last Decade

P. Poortmans

25 papers receiving 318 citations

Peers

Countries citing papers authored by P. Poortmans

Since Specialization

Citations

This map shows the geographic impact of P. Poortmans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Poortmans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Poortmans more than expected).

Fields of papers citing papers by P. Poortmans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Poortmans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Poortmans. The network helps show where P. Poortmans may publish in the future.

Co-authorship network of co-authors of P. Poortmans

This figure shows the co-authorship network connecting the top 25 collaborators of P. Poortmans. A scholar is included among the top collaborators of P. Poortmans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Poortmans. P. Poortmans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	259TiP Treatment of oligometastatic breast cancer (OMBC): A randomised phase III trial comparing stereotactic ablative radiotherapy (SABR) and systemic treatment with systemic treatment alone as first-line treatment - TAORMINA 2023 ·ESMO Open ·Barbro Linderholm,Antonios Valachis,Vidar G. Flote,P. Poortmans,(unknown),(unknown),Séamus O’Reilly,Frances Duane,Tanja Marinko,(unknown),Anne Andersson,Jenny Bergqvist,Theodoros Foukakis,(unknown),Katarzyna Kulbacka-Ortiz,(unknown),(unknown),Dan Lundstedt,Icro Meattini	2
2	PO-0918: Consensus on target volume delineation and treatment planning strategy for the DBCG RT Recon trial 2018 ·Radiotherapy and Oncology ·Henrik Dahl Nissen,Esben Svitzer Yates,(unknown),L. Boersma,Kristina S. Boye,Ruth R Canter,(unknown),(unknown),(unknown),(unknown),I. Jensen,Ebbe Laugaard Lorenzen,Ingvil Mjaaland,(unknown),Orit Kaidar‐Person,P. Poortmans,Johan Vikström,J.A.W. Webb,Birgitte Vrou Offersen	4
3	OC-0568: Accelerated PBI VS standard radiotherapy (IRMA trial): interim cosmetic and toxicity results 2017 ·Radiotherapy and Oncology ·Bruno Meduri,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),A.G. Morganti,Salvatore Parisi,Shaniko Kaleci,Frank Lohr,Roberto D’Amico,P. Poortmans,Francesco Bertoni,G.P. Frezza	16
4	Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients 2017 ·European Journal of Cancer ·Mirelle Lagendijk,Marissa C. van Maaren,(unknown),(unknown),P. Poortmans,Linetta B. Koppert,Madeleine M.A. Tilanus‐Linthorst,Sabine Siesling	17
5	1808 Treatment patterns for older patients with non-metastatic breast cancer in four European countries - preliminary data from a EURECCA international comparison 2015 ·European Journal of Cancer ·Marloes G.M. Derks,M. Kiderlen,Denise E. Hilling,Esther Bastiaannet,Petra G. Boelens,Sabine Siesling,Erik V. Van der Eycken,P C Walsh,Josep M. Borràs,Riccardo A. Audisio,P. Poortmans,C.J.H. Van de Velde	2
6	02 Results of EORTC 22991: 3D-CRT/IMRT with or without 6-month androgen deprivation therapy in localized T1b-cT2aN0M0 prostate cancer (EORTC 22991) 2014 ·European Urology Supplements ·M. Bolla,P. Maingon,An Van den Bergh,C. Carrié,S. Villà,Petros Kitsios,P. Poortmans,Santhanam Sundar,E. van der Steen-Banasik,Laurence Collette	2
7	6LBA The benefit of regional irradiation in stage I–III breast cancer: 10 years results of the EORTC ROG and BCG phase III trial 22922/10925 2014 ·European Journal of Cancer ·H. Struikmans,Sandra Collette,W. Van den Bogaert,(unknown),Volker Budach,(unknown),Mariacarla Valli,Alain Fourquet,H. Bartelink,P. Poortmans	8
8	OC-0522: 3D-CRT/IMRT with/without short term androgen deprivation in localized T1b-cT2aN0M0 prostate cancer (EORTC 22991) 2014 ·Radiotherapy and Oncology ·M. Bolla,P. Maingon,(unknown),C. Carrié,S. Villà,Petros Kitsios,P. Poortmans,Santhanam Sundar,Elzbieta M. van der Steen‐Banasik,Laurence Collette	1
9	OC-0523: Lymph node RT improves survival in breast cancer: 10 years results of the EORTC ROG and BCG phase III trial 22922/10925. 2014 ·Radiotherapy and Oncology ·P. Poortmans,H. Struikmans,Sandra Collette,(unknown),Volker Budach,(unknown),(unknown),Alain Fourquet,W. Van den Bogaert,Harry Bartelink	11
10	The Essential Role of Radiotherapy in the Treatment of Merkel Cell Carcinoma: A Study From the Rare Cancer Network 2011 ·International Journal of Radiation OncologyBiologyPhysics ·Pirus Ghadjar,Johannes H.A.M. Kaanders,P. Poortmans,Renata Zaucha,Marco Krengli,J. L. Lagrange,(unknown),Tan Dat Nguyen,Raymond Miralbell,(unknown),N. Boujelbene,(unknown),Luciano Scandolaro,M. Untereiner,Hadassah Goldberg,Gianfranco Pesce,Yavuz Anacak,(unknown),Daniel M. Aebersold,Karl T. Beer	52
11	Cancers de prostate : quelle place pour la radiothérapie à visée curative chez les patients âgés ? 2009 ·Cancer/Radiothérapie ·Thomas Nguyen,D. Azria,(unknown),P. Poortmans,Robert C. Miller	1
12	The impact of a boost dose on the local recurrence rate in high risk patients after breast conserving therapy – results from the EORTC boost-no boost trial 2008 ·European Journal of Cancer Supplements ·Helen Jones,Ninja Antonini,Laurence Collette,Alain Fourquet,W.J. Hoogenraad,J.J. Jager,Hans Peterse,P. Poortmans,H. Struikmans,Harry Bartelink	0
13	The Impact of Boost Dose and Margins on the Local Recurrence Rate in Breast Conserving Therapy: Results From the EORTC Boost-No Boost Trial 2007 ·International Journal of Radiation OncologyBiologyPhysics ·Helen Jones,Ninja Antonini,(unknown),Alain Fourquet,W.J. Hoogenraad,W. Van den Bogaert,J.J. Jager,P. Poortmans,H. Struikmans,Harry Bartelink	6
14	A population-based study of radiotherapy in a cohort of patients with rectal cancer diagnosed between 1996 and 2000 2007 ·European Journal of Surgical Oncology ·(unknown),Marieke W.J. Louwman,Marnix L.M. Lybeert,P. Poortmans,H.J.T. Rutten,S.J. Brenninkmeijer,J.W.W. Coebergh	10
15	The influence of the boost technique on local control in breast conserving treatment in the EORTC ‘boost versus no boost’ trial 2004 ·European Journal of Cancer Supplements ·P. Poortmans,H. Bartelink,(unknown),H. Struikmans,W. Van den Bogaert,Alain Fourquet,J.J. Jager,W.J. Hoogenraad,Patrick Rodrigus,Carla C. Wárlám-Rodenhuis,Laurence Collette,M. Piérart	18
16	Significance of margins of excision on breast cancer recurrence (on behalf of the EORTC Radiotherapy, Breast Cancer Groups) 2004 ·European Journal of Cancer Supplements ·Heather Jones,Ninja Antonini,(unknown),Alain Fourquet,W.J. Hoogenraad,Jean-Claude Horiot,P. Poortmans,J.J. Jager,W. Van den Bogaert,H. Bartelink	3
17	Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? 2003 ·European Journal of Cancer ·Conny Vrieling,Laurence Collette,Alain Fourquet,W.J. Hoogenraad,Jean-Claude Horiot,J.J. Jager,S.B. Oei,Hans Peterse,M. Piérart,P. Poortmans,H. Struikmans,W. Van den Bogaert,Harry Bartelink	130
18	Outcome after combined modality treatment for primary adenocarcinoma of the anal canal: a rare cancer network multicenter study 2001 ·International Journal of Radiation OncologyBiologyPhysics ·Yazid Belkacémi,Christine Berger,P. Poortmans,A. Zouhair,Jean‐Baptiste Méric,(unknown),Thomas Nguyen,Marco Krengli,(unknown),E. Touboul	2
19	Impact of a boost dose of 16 GY on the local control and cosmesis in patients with early breast cancer: The EORTC ‘boost versus no boost’ trial 2000 ·International Journal of Radiation OncologyBiologyPhysics ·Harry Bartelink,Laurence Collette,Alain Fourquet,Jean-Claude Horiot,J.J. Jager,J.L. Peterse,M. Piérart,P. Poortmans,H. Struikmans,W. Van den Bogaert	28
20	Set-up accuracy for pelvic fields after application of a 3-d correction procedure using digital portal imaging 1994 ·International Journal of Radiation OncologyBiologyPhysics ·Pieter H. Vos,Arjan Bel,P. Poortmans,(unknown),Patrick Rodrigus,(unknown)	3

About P. Poortmans

P. Poortmans is a scholar working on Cancer Research, Radiation and Pulmonary and Respiratory Medicine, having authored 26 papers that have together received 328 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (12 papers), Advanced Radiotherapy Techniques (6 papers) and Prostate Cancer Treatment and Research (5 papers). The work is most often cited by research in Cancer Research (229 citations), Pathology and Forensic Medicine (130 citations) and Oncology (164 citations). P. Poortmans has collaborated with scholars based in Netherlands, France and Belgium. Frequent co-authors include Alain Fourquet, W. Van den Bogaert, H. Struikmans, J.J. Jager, Laurence Collette, M. Piérart, Harry Bartelink, Jean-Claude Horiot, W.J. Hoogenraad and S.B. Oei. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, European Journal of Cancer and Radiotherapy and Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact